Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21651804 | 0.85 | MAPT (0.98) | MAPTALDH1A1USP2RXFP1LMNA | |
| SCHEMBL23711014 | 0.84 | MAPT (0.81) | MAPTALDH1A1USP2TSHRRXFP1 | |
| SCHEMBL8289604 | 0.82 | MAPT (0.78) | MAPTALDH1A1USP2TSHRRXFP1 | |
| SCHEMBL8288656 | 0.82 | MAPT (0.84) | MAPTALDH1A1USP2TSHRTP53 | |
| SCHEMBL21247263 | 0.81 | MAPT (0.96) | MAPTALDH1A1USP2TSHRTP53 | |
| SCHEMBL8290510 | 0.81 | MAPT (0.77) | MAPTALDH1A1TP53LMNAKMT2A | |
| SCHEMBL7892222 | 0.81 | MAPT (0.84) | MAPTALDH1A1USP2GAATP53 | |
| SCHEMBL14209281 | 0.81 | TP53 (0.82) | MAPTALDH1A1USP2CYP1A2GAA | |
| SCHEMBL3914054 | 0.80 | MAPT (0.82) | MAPTALDH1A1USP2GAARXFP1 | |
| SCHEMBL3917114 | 0.80 | MAPT (0.82) | MAPTALDH1A1USP2GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051220-A1 | COMPOUNDS FOR USE IN THERAPY | GLUCOX BIOTECH AB (SE) | 2015-02-19 | — | — | US | disclosed |
| EP-2825165-A1 | THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY | Glucox Biotech AB (SE) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013135803-A1 | THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY | GLUCOX BIOTECH AB (SE) | 2013-09-19 | — | — | WO | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051220-A1 | COMPOUNDS FOR USE IN THERAPY | XDH, PNPO, OAT | MAPT 1102/4885ALDH1A1 132/4885USP2 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.